Evidence map›Paper›PMID 40024740›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Spontaneous Remission in a Patient with Anti-OJ Autoantibodies-positive Anti-synthetase Syndrome Following SARS-CoV-2 Infection and mRNA Vaccination.

Yasuyuki Todoroki, Shingo Nakayamada, Ippei Miyagawa, Satoshi Kubo, Kiyotake Yoshioka, Minoru Satoh, Yoshiya Tanaka

Abstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yasuyuki TodorokiFirst Department of Internal Medicine, University of Occupational and Environmental Health, Japan.
Shingo NakayamadaFirst Department of Internal Medicine, University of Occupational and Environmental Health, Japan.
Ippei MiyagawaFirst Department of Internal Medicine, University of Occupational and Environmental Health, Japan.
Satoshi KuboFirst Department of Internal Medicine, University of Occupational and Environmental Health, Japan.
Kiyotake YoshiokaFirst Department of Internal Medicine, University of Occupational and Environmental Health, Japan.
Minoru SatohDepartment of Human, Information and Life Sciences, University of Occupational and Environmental Health, Japan.
Yoshiya TanakaFirst Department of Internal Medicine, University of Occupational and Environmental Health, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-synthetase syndrome (ASyS) is a subset of idiopathic inflammatory myopathies characterized by a triad of myositis, interstitial lung disease, and arthritis. Patients with ASyS are generally treated with glucocorticoids, immunosuppressants, or both. We encountered a 53-year-old woman who developed anti-OJ autoantibodies-positive anti-synthetase syndrome following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and CoV-2 messenger RNA (mRNA) vaccination. Her dyspnea and rash resolved within 4 weeks of the initial examination, achieving spontaneous remission without treatment 52 weeks after the diagnosis. This case suggests a potential association between SARS-CoV-2 infection, mRNA vaccination, and the transient development of anti-OJ antibodies-positive ASyS.

Indexed as

AutoantibodiesCOVID-19COVID-19 VaccinesMyositisFemaleHumansMiddle AgedRemission, SpontaneousSARS-CoV-2AutoantibodiesCOVID-19 Vaccinesanti-synthetase syndromeSARS-CoV-2 infectionSARS-CoV-2 mRNA vaccinationspontaneous remission

Identifiers

PMID40024740
PMCPMC12463430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.